A case report: The first show phenomenon in the treatment of spinal cord injury with Regentime procedure using autologous bone marrow-derived stem cells

Clin Case Rep, 2023 · DOI: 10.1002/ccr3.7568 · Published: May 28, 2023

Spinal Cord Injury Regenerative Medicine Neurology

Simple Explanation

This case report discusses a novel stem cell therapy, called Regentime, for spinal cord injuries. The patient, a 40-year-old male, experienced improved sensation in his lower limbs shortly after the stem cell transplant. This early improvement is termed “the first show phenomenon.” Although the initial improvements declined after a few weeks, the patient experienced no serious complications. The study suggests that the Regentime procedure, which uses the patient’s own bone marrow-derived stem cells, appears to be a safe treatment option for spinal cord injuries.

Study Duration

Not specified

Participants

A 40-year-old male with T9 spinal cord injury

Evidence Level

Case Report

Key Findings

1
The patient regained sensation to light touch in his lower limbs within the first week post-transplantation.
2
The early symptom improvement was termed “the first show phenomenon.”
3
The initial improvements declined 2–3 weeks after transplantation, indicating a transient effect.

Research Summary

This case report presents the “first show phenomenon” observed after Regentime stem cell therapy in a spinal cord injury patient. The patient, who had complete motor and sensory loss due to a T9 injury, received autologous bone marrow-derived mononuclear stem cells. During the first week post-transplantation, the patient regained sensation to light touch in his lower limbs. No serious complications were reported. The study suggests that the Regentime procedure is safe and potentially effective for SCI patients, although the initial improvements may be transient.

Practical Implications

Potential for New SCI Treatment

The Regentime procedure, using autologous stem cells, shows promise as a safe and potentially effective treatment for spinal cord injuries, warranting further investigation.

Understanding the 'First Show Phenomenon'

The observed 'first show phenomenon' provides valuable insights into the early effects of stem cell therapy on SCI and may guide future therapeutic strategies.

Personalized Medicine Approach

Utilizing autologous stem cells minimizes the risk of rejection and allows for a personalized approach to treating spinal cord injuries.

Study Limitations

1
The study is a single case report, limiting the generalizability of the findings.
2
The improvements observed were transient, suggesting the need for further optimization of the therapy.
3
Longer follow-up duration is needed to assess the long-term efficacy and potential adverse effects of the therapy.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury